The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
< 0.100 Eu/µg
The ED50, determined by the dose-dependent stimulation of the proliferation of human TF-1 cells, is < 0.2 ng/ml, corresponding to a specific activity of > 5 x 106 units/mg.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
B cell growth factor 1
B cell IgG differentiation factor
B Cell Stimulatory Factor 1
B-cell stimulatory factor 1
IGG1 induction factor
Interleukin 4 variant 2
Interleukin 4, isoform 1
Lymphocyte stimulatory factor 1
Participates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes.
Involvement in disease
Genetic variations in IL4 may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.